Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket

Published 12/07/2023, 13:19
Updated 12/07/2023, 14:40
© Reuters.  Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket

Benzinga - Gainers

  • Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday.
  • Healthcare Triangle, Inc. (NASDAQ: HCTI) shares gained 64.7% to $5.37 in pre-market trading after adding over 8% on Tuesday.
  • FLJ Group Limited (NASDAQ: FLJ) shares rose 27.1% to $0.3661 in pre-market trading after declining around 5% on Tuesday.
  • Enochian Biosciences Inc. (NASDAQ: ENOB) shares rose 26.4% to $0.6321 in pre-market trading. On July 7, 2023, Enochian Biosciences received a deficiency notice from the Nasdaq Stock Market informing the company that its common stock, par value $0.0001 per share, failed to comply with the $1 minimum bid price.
  • Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) gained 22.7% to $9.30 in pre-market trading. Eloxx Pharmaceuticals shares jumped 94% on Tuesday after Oppenheimer raised its price target from $50 to $55.
  • Vivos Therapeutics, Inc. (NASDAQ: VVOS) gained 10.3% to $0.57 in pre-market trading.
  • Data Storage Corporation (NASDAQ: DTST) rose 9.8% to $2.79 in pre-market trading. Data Storage recently reported a large, subscription-based contract with a leading promotional products company.
  • CBL International Limited (NASDAQ: BANL) rose 9.1% to $5.44 in pre-market trading after jumping over 12% on Tuesday.
  • Ascent Solar Technologies, Inc. (NASDAQ: ASTI) shares climbed 8% to $0.1242 in pre-market trading. Ascent Solar Technologies recently reported bridge financing of up to 900 series 1B convertible preferred shares for $1,000 per share for aggregate gross proceeds of $900,000.
  • ImmuCell Corporation (NASDAQ: ICCC) shares gained 4.2% to $5.19 in pre-market trading. ImmuCell reported preliminary sales of $3.53 million for the second quarter, down from $3.86 million in the previous year.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Losers
  • Silk Road Medical, Inc (NASDAQ: SILK) fell 22.1% to $25.43 in pre-market trading. Silk Road Medical is expected to report financial results for the second quarter 2023 on Aug. 1, 2023. JP Morgan downgraded Silk Road Medical from Overweight to Neutral and lowered the price target from $50 to $28.
  • ShiftPixy, Inc. (NASDAQ: PIXY) fell 20.9% to $1.89 in pre-market trading.
  • PainReform Ltd. (NASDAQ: PRFX) fell 19.2% to $13.33 in pre-market trading after jumping 307% on Tuesday.
  • Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) fell 12.9% to $5.25 in pre-market trading after surging 42% on Tuesday.
  • Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) shares fell 11.4% to $0.3411 in pre-market trading. Adial Pharmaceuticals shares jumped 90% on Tuesday after the company provided business update following favorable comments from US, EU regulatory meetings.
  • WANG & LEE GROUP, Inc. (NASDAQ: WLGS) shares fell 11% to $1.38 in pre-market trading after rising over 20% on Tuesday.
  • CytoMed Therapeutics Limited (NASDAQ: GDTC) shares dropped 9.8% to $5.09 in pre-market trading after climbing 62% on Tuesday.
  • Cingulate Inc. (NASDAQ: CING) fell 9.4% to $0.77 in pre-market trading. Cingulate recently announced top-line results from its Phase 3 adult efficacy and safety trial of CTx-1301 for ADHD.
  • Crown ElectroKinetics Corp. (NASDAQ: CRKN) fell 7.3% to $0.1009 in pre-market after gaining around 7% on Tuesday.
  • Purple Biotech Ltd. (NASDAQ: PPBT) fell 6.2% to $1.29 in pre-market trading. Purple Biotech recently reported results of CM24 dose escalation in advanced pancreatic cancer patients.

Now Read This: Investor Optimism Improves Ahead Of Inflation Data

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.